SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novartis pelacarsen misses primary endpoint in Phase 3 study

Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce cardiovascular events versus placebo.

NOT

Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study. The company said on Friday that pelacarsen did not cut the risk of cardiovascular events, including deaths, heart attacks and strokes, versus placebo. The drug did succeed…

Related stories